These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27137221)

  • 1. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
    Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
    Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
    Ballard C; Corbett A; Chitramohan R; Aarsland D
    Curr Opin Psychiatry; 2009 Nov; 22(6):532-40. PubMed ID: 19696673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
    Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
    CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agitation and aggression in people with Alzheimer's disease.
    Ballard C; Corbett A
    Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
    Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL
    Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
    Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
    Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of agitation and aggression associated with Alzheimer disease.
    Ballard CG; Gauthier S; Cummings JL; Brodaty H; Grossberg GT; Robert P; Lyketsos CG
    Nat Rev Neurol; 2009 May; 5(5):245-55. PubMed ID: 19488082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis.
    Ruthirakuhan M; Lanctôt KL; Vieira D; Herrmann N
    J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30753761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
    Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
    Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids for Agitation in Alzheimer's Disease.
    Outen JD; Burhanullah MH; Vandrey R; Amjad H; Harper DG; Patrick RE; May RL; Agronin ME; Forester BP; Rosenberg PB
    Am J Geriatr Psychiatry; 2021 Dec; 29(12):1253-1263. PubMed ID: 33573996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
    Davies SJ; Burhan AM; Kim D; Gerretsen P; Graff-Guerrero A; Woo VL; Kumar S; Colman S; Pollock BG; Mulsant BH; Rajji TK
    J Psychopharmacol; 2018 May; 32(5):509-523. PubMed ID: 29338602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychotic symptoms, aggression and restlessness in dementia.
    Ballard C; Gray A; Ayre G
    Rev Neurol (Paris); 1999; 155 Suppl 4():S44-52. PubMed ID: 10637938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease.
    Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):289-303. PubMed ID: 38822731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia].
    Caparros-Lefebvre D; Dewailly D
    Rev Neurol (Paris); 2005 Nov; 161(11):1071-8. PubMed ID: 16288172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.